Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Oil & Gas, Consumer Goods and Financials sectors led shares lower. At the close in NYSE, the...
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Oil & Gas, Technology and Consumer Services sectors led shares higher. At the close in NYSE, the...
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Industrials, Basic Materials and Technology sectors led shares higher. At the close in NYSE, the...
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced that two-year follow-up data from the SCLERADEC-I pilot study in patients with hand dysfunction associated with scleroderma when...
Cytori Therapeutics Inc (NASDAQ:CYTX) Cytori Therapeutics is having an incredibly strong day in the market today, and for good reason. The company announced a number of key...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Neutral||Sell||Sell||Strong Sell||Strong Sell|
|Technical Indicators||BUY||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Summary||Neutral||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Falling Three Methods||1H||Current|
|Bullish Engulfing||1M||1||Aug 19|
|Bullish doji Star||5H||2||Sep 18, 2019 03:00AM|
|Bullish doji Star||1M||3||Jun 19|
|Bank of America||30.00||30.15||29.55||+0.06||+0.20%||66.75M||18/09|
Plus Therapeutics, Inc., formerly Cytori Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.